GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Earnings per Share (Diluted)

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Earnings per Share (Diluted) : HK$1.88 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Earnings per Share (Diluted)?

SciClone Pharmaceuticals (Holdings)'s Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$0.83. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.88.

SciClone Pharmaceuticals (Holdings)'s EPS (Basic) for the six months ended in Dec. 2023 was HK$0.91. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2.00.

SciClone Pharmaceuticals (Holdings)'s EPS without NRI for the six months ended in Dec. 2023 was HK$0.85. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.90.

During the past 12 months, SciClone Pharmaceuticals (Holdings)'s average EPS without NRIGrowth Rate was 30.90% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 12.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 15.50% per year.

During the past 7 years, SciClone Pharmaceuticals (Holdings)'s highest 3-Year average EPS without NRI Growth Rate was 242.50% per year. The lowest was 12.80% per year. And the median was 17.45% per year.


SciClone Pharmaceuticals (Holdings) Earnings per Share (Diluted) Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) Earnings per Share (Diluted) Chart

SciClone Pharmaceuticals (Holdings) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial 1.01 1.32 1.63 1.35 1.88

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.50 0.88 0.51 1.05 0.83

Competitive Comparison of SciClone Pharmaceuticals (Holdings)'s Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals (Holdings)'s PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SciClone Pharmaceuticals (Holdings)'s PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals (Holdings)'s PE Ratio distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals (Holdings)'s PE Ratio falls into.



SciClone Pharmaceuticals (Holdings) Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

SciClone Pharmaceuticals (Holdings)'s Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(1227.113-0)/650.433
=1.89

SciClone Pharmaceuticals (Holdings)'s Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(537.832-0)/643.744
=0.84

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


SciClone Pharmaceuticals (Holdings)  (HKSE:06600) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


SciClone Pharmaceuticals (Holdings) Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Traded in Other Exchanges
N/A
Address
381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN
SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.
Executives
Ubs Group Ag 2201 Interest of corporation controlled by you
Zhao Hong 2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang 2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited 2501 Other
Ascendent Capital Partners Ii Gp Limited 2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p. 2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p. 2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited 2101 Beneficial owner
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Bank Of China Limited 2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited 2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines